Literature DB >> 2142253

Effects of iron and desferrioxamine on Rhizopus infection.

F Abe1, H Inaba, T Katoh, M Hotchi.   

Abstract

To investigate the association among iron, desferrioxamine, and a Rhizopus infection, the influence of iron and/or desferrioxamine on experimental mucormycosis in mice was examined. All mice pretreated with iron, desferrioxamine, or a combination of iron and desferrioxamine died within 5 days after the inoculation of R. oryzae. In the mice fungal lesions were observed in the brain which resembled human cerebral mucormycosis. By contrast, the mortality in the control mice with R. oryzae was 20% through the 3-week experimental period. Therefore, it was demonstrated that iron as well as desferrioxamine administration markedly promotes the growth of R. oryzae. The increased susceptibility to R. oryzae was considered to be due to increased serum iron in the animals pretreated with iron only; however, pretreatment with desferrioxamine did not affect the amount of serum ion. Thus, the data suggest that desferrioxamine acts as a siderophore to R. oryzae and exerts an adverse effect on mucormycosis. This study has shown that the presence of iron and desferrioxamine enhances the virulence and pathogenicity of R. oryzae by serving as a growth factor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142253     DOI: 10.1007/bf00446996

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  13 in total

1.  Mucormycosis in deferoxamine-treated patients on dialysis.

Authors:  J H Veis; R Contiguglia; M Klein; J Mishell; A C Alfrey; J I Shapiro
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

2.  Yersinia hepatic abscesses and iron overload.

Authors:  C Chiesa; L Pacifico; F Renzulli; M Midulla; L Garlaschi
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

Review 3.  Iron and infection.

Authors:  E D Weinberg
Journal:  Microbiol Rev       Date:  1978-03

Review 4.  Microbial iron compounds.

Authors:  J B Neilands
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

Review 5.  Ocular and orbital phycomycosis.

Authors:  J N Schwartz; E H Donnelly; G K Klintworth
Journal:  Surv Ophthalmol       Date:  1977 Jul-Aug       Impact factor: 6.048

6.  Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine.

Authors:  D W Windus; T J Stokes; B A Julian; A Z Fenves
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

7.  Hydroxamate siderophore production by opportunistic and systemic fungal pathogens.

Authors:  M Holzberg; W M Artis
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

Review 8.  The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.

Authors:  J R Boelaert; G F van Roost; P L Vergauwe; J J Verbanck; C de Vroey; M F Segaert
Journal:  Clin Nephrol       Date:  1988-05       Impact factor: 0.975

9.  Experimental candidiasis in iron overload.

Authors:  F Abe; M Tateyma; H Shibuya; N Azumi; Y Ommura
Journal:  Mycopathologia       Date:  1985-01       Impact factor: 2.574

10.  Intestinal mucormycosis in hemodialysis patients following deferoxamine.

Authors:  A R Eiser; R F Slifkin; M S Neff
Journal:  Am J Kidney Dis       Date:  1987-07       Impact factor: 8.860

View more
  19 in total

1.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Peter V Chin-Hong; Dimitrios P Kontoyiannis; Michele I Morris; John R Perfect; David Fredricks; Eric P Brass
Journal:  J Antimicrob Chemother       Date:  2011-09-20       Impact factor: 5.790

2.  Eighty Years of Mycopathologia: A Retrospective Analysis of Progress Made in Understanding Human and Animal Fungal Pathogens.

Authors:  Vishnu Chaturvedi; Jean-Philippe Bouchara; Ferry Hagen; Ana Alastruey-Izquierdo; Hamid Badali; Anamelia Lorenzetti Bocca; Jose F Cano-Lira; Cunwei Cao; Sudha Chaturvedi; Sanjay H Chotirmall; Anne D van Diepeningen; Jean-Pierre Gangneux; Jesus Guinea; Sybren de Hoog; Macit Ilkit; Rui Kano; Weida Liu; Nilce M Martinez-Rossi; Marcia de Souza Carvalho Melhem; Mario Augusto Ono; Yuping Ran; Stephane Ranque; Celia Maria de Almeida Soares; Takashi Sugita; Philip A Thomas; Anna Vecchiarelli; Nancy L Wengenack; Patrick C Y Woo; Jianping Xu; Rosely M Zancope-Oliveira
Journal:  Mycopathologia       Date:  2018-11-30       Impact factor: 2.574

3.  The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence.

Authors:  Anna H T Hissen; Adrian N C Wan; Mark L Warwas; Linda J Pinto; Margo M Moore
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus.

Authors:  Anna H T Gifford; Jodine R Klippenstein; Margo M Moore
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 6.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

Review 7.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

8.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy.

Authors:  Hector M Reyes; Eric J Tingle; Andrew Z Fenves; Jennifer Spiegel; Elizabeth C Burton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-10

10.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.